NSE · Healthcare · Drug Manufacturers - Specialty & Generic
with an average price target of ₹281.97.
| Document | Date |
|---|---|
| Quarterly results · Q1 FY27 SUVEN LIFE SCIENCES LIMITED – Q1 FY2027 SUMMARY HEADLINE NUMBERS • Quarter ended 30 June 2026 (Consolidated basis): - Total Income: Rs 110.89 mill | 2026-08-06 |
| Annual report FY2026 SUVEN LIFE SCIENCES LIMITED — FY2025-26 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Revenue (FY26): ₹21.05 crore vs ₹17.55 crore (FY25) — i | 2026-07-30 |
| Investor presentation · Q4 FY26 SUVEN LIFE SCIENCES LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Company: Suven Life Sciences Limited, clinical-stage biopharmaceutical company foc | 2026-06-12 |
| Quarterly results · Q4 FY26 SUVEN LIFE SCIENCES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Standalone FY2026 Revenue from Operations: Rs 711.47 lakhs (up 6.9% vs FY2025: Rs | 2026-05-13 |
| Quarterly results · Q3 FY26 SUVEN LIFE SCIENCES LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Q3 FY2026 (Standalone): Revenue from operations Rs. 280.87 lakhs; Net loss Rs. 1,3 | 2026-01-29 |
| Quarterly results · Q2 FY26 SUVEN LIFE SCIENCES LIMITED – FINANCIAL SUMMARY Document Date: 11 November 2025 | Reporting Period: Q2 FY2025-26 (ended 30 Sept 2025) --- HEADLINE N | 2025-11-11 |
| Quarterly results · Q1 FY26 SUVEN LIFE SCIENCES LIMITED – Q1 FY2025-26 RESULTS SUMMARY HEADLINE NUMBERS STANDALONE BASIS (Quarter ended June 30, 2025): • Revenue from operation | 2025-08-13 |
| Annual report FY2025 SUVEN LIFE SCIENCES LIMITED – ANNUAL REPORT 2024-25 SUMMARY HEADLINE NUMBERS • Revenue (FY25): ₹7 crore (down from ₹13 crore in FY21) • EBITDA (FY25 | 2025-07-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Suven Life Sciences Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.